Prelude Capital Management’s Viridian Therapeutics VRDN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $243K | Sell |
17,401
-50,268
| -74% | -$703K | 0.02% | 708 |
|
|
2025
Q1 | $912K | Buy |
+67,669
| New | +$912K | 0.07% | 276 |
|
|
2024
Q4 | – | Sell |
-51,050
| Closed | -$1.16M | – | 1466 |
|
|
2024
Q3 | $1.16M | Buy |
+51,050
| New | +$1.16M | 0.07% | 297 |
|
|
2018
Q3 | – | Sell |
-400
| Closed | -$38K | – | 1693 |
|
|
2018
Q2 | $38K | Buy |
400
+67
| +20% | +$6.37K | ﹤0.01% | 946 |
|
|
2018
Q1 | $35K | Buy |
333
+66
| +25% | +$6.94K | ﹤0.01% | 1029 |
|
|
2017
Q4 | $42K | Sell |
267
-166
| -38% | -$26.1K | ﹤0.01% | 857 |
|
|
2017
Q3 | $59K | Buy |
433
+42
| +11% | +$5.72K | 0.01% | 951 |
|
|
2017
Q2 | $76K | Buy |
391
+47
| +14% | +$9.14K | 0.01% | 783 |
|
|
2017
Q1 | $64K | Buy |
344
+177
| +106% | +$32.9K | 0.01% | 856 |
|
|
2016
Q4 | $13K | Buy |
+167
| New | +$13K | ﹤0.01% | 1309 |
|